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Abstract. – OBJECTIVE: Omega-3 fatty acids 
are commonly used as a lipid-lowering agent or 
dietary supplement for the purpose of preven-
tion of cardiovascular diseases. However, even 
large-scale clinical trials have not shown signif-
icant results demonstrating clear clinical bene-
fits in cardiovascular diseases. Thus, this um-
brella review aims to summarize and evaluate 
the evidence of clinical effects of omega-3 fat-
ty acids supplementation on cardiovascular out-
comes through comprehensive analyses of pre-
vious randomized controlled trials (RCTs) or 
observational cohort studies.
MATERIALS AND METHODS: We conducted 
relevant publication search in PubMed, Embase, 
and Cochrane Database of Systematic Reviews. 
We retrieved and analyzed 3,298 articles pub-
lished until August 28th, 2019.
RESULTS: We identified 29 relevant articles 
and analyzed 83 meta-analyses of RCTs or co-
hort studies therefrom. As a result, we identified 
12 cardiovascular outcomes that are related to 
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omega-3 fatty acids supplementation. Among 
them, total mortality from major cardiovascular 
causes (RR 0.92, 95% CI 0.86 to 0.98) had signifi-
cant inverse associations, and moreover, statis-
tical significances were maintained even in sub-
group analysis of large scale RCTs including 
more than 1,000 patients (RR 0.94, 95% CI 0.88 
to 0.99).
CONCLUSIONS: Our umbrella review study 
shows that omega-3 fatty acids supplementation 
have a clinical benefit in reducing mortality from 
cardiovascular causes. However, many studies 
still have shown conflicting results, and there-
fore, further studies will be needed to verify the 
clinical benefit of omega-3 supplementation.
Key Words: 
Omega-3 fatty acids, Cardiovascular outcome, 
Mortality, Meta-analysis, Systematic review.
Introduction
In the general population and among health-
care professionals, it is widely recognized that 
omega-3 fatty acids exhibit properties that can 
potentially prevent cardiovascular diseases1. 
However, controversy still exists due to discrep-
ancies between available evidences2. Significant 
results in clinical trials and observational studies 
of small patient groups have been reported3-5, but 
the true association remains unclear, as large clin-
ical trials have often reported non-significant re-
sults6-8. Furthermore, the recently published Vita-
min D and Omega-3 (VITAL) trial, a large-sized 
randomized controlled trial (RCT) that recruited 
25,871 patients, concluded that marine omega-3 
fatty acids supplementation has no effects in pre-
venting cardiovascular diseases9.
Therefore, although systematic reviews and 
meta-analyses have attempted to synthesize the 
results from numerous clinical trials and observa-
tional studies investigating the effect of omega-3 
supplementation on cardiovascular outcomes, 
they reached no definite conclusion. Several re-
cent systematic reviews have performed quanti-
tative syntheses of the vast amount of available 
evidences. Among them, a recent systemic review 
indicated the beneficial effect of omega-3 supple-
mentation on cardiovascular diseases10, while the 
other review showed the positive effect of ome-
ga-3 fatty acids but only a small effect with mod-
erate- and low-certainty evidence11.
The aim of this umbrella review was, therefore, 
to examine the effect of omega-3 fatty acids sup-
plementation on cardiovascular diseases avoid-
ing research biases, and thereby overcoming the 
shortcomings of previous studies. 
Materials and Methods 
We performed an umbrella review assessing 
the effects of omega-fatty acids supplementa-
tion on cardiovascular outcomes according to a 
pre-registered protocol in PROSPERO (registra-
tion number: CRD42018115797). We reported the 
results according to Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses guide-
lines (PRISMA)12.
Literature Search Strategy and
Eligibility Criteria
We searched PubMed, Embase, and Cochrane 
Database of Systematic Reviews (CDSR) from 
their inception to August 28th, 2019 to identify 
meta-analyses that investigated the association 
between omega-3 supplementation and cardio-
vascular outcomes. We performed a publication 
search using the following keywords: omega-3 
fatty acids, n-3 fatty acids, w-3 fatty acids, α-lino-
lenic acid, ALA, eicosapentaenoic acid, EPA, do-
cosahexaenoic acid, DHA, polyunsaturated fatty 
acids, PUFA, long chain polyunsaturated fatty 
acids, LCPUFA, fish oil, and meta.
Only English articles were eligible. We first 
screened titles, followed by the abstract, and then 
the full text of potentially eligible articles. We 
only included systematic reviews containing me-
ta-analyses that investigated the effect of omega-3 
fatty acids supplementation on cardiovascular dis-
ease. On the other hand, we did not include studies 
on the relationship between fish consumption and 
cardiovascular outcome, because fish contains 
various nutrients other than omega-3 fatty acids. 
For example, a RCT that examined the difference 
in effects of between fresh fish consumption and 
omega-3 fatty acids supplementation concluded 
that fish consumption was associated with posi-
tive cardiovascular outcomes, but omega-3 fatty 
acids supplementation was not13. In addition, we 
excluded meta-analyses that studied dietary in-
terventions such as Mediterranean diet education 
and food frequency questionnaire results.
Inclusion of meta-analysis was independent 
of the study design of the component study (i.e. 
either RCTs or observational studies). There was 
no restriction of the study population. If an article 
included more than one eligible meta-analysis, we 
included these separately.
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Data Extraction
From each eligible article, we extracted the 
name of the first author and the date of publica-
tion. From each eligible meta-analysis, we ex-
tracted the outcome of interest, the number of 
cardiovascular outcome events and total partici-
pants, individual study estimates and correspond-
ing 95% confidence interval (CI), metrics used 
for analyses such as odds ratio (OR), risk ratio 
(RR), and hazard ratio (HR), and individual study 
designs as RCT or observational study. We also 
extracted the summary effect estimates and me-
ta-analysis model of the original meta-analyses to 
check whether the original results were consistent 
with the results of our re-analysis. From the me-
ta-analyses of observational studies, we extracted 
the maximally adjusted study estimate available. 
Statistical Analysis
We estimated the summary effects, corre-
sponding 95% CIs and p-values using both fixed- 
and random-effects models14. We also estimated 
between-study heterogeneity as the I2 metric15,16. 
I2 statistic above 50% and 75% are usually judged 
to represent large and very large heterogeneity, 
respectively17. To assess the reliability of anal-
yses, we adopted a series of statistical tests and 
bias assessment methods. We estimated the 95% 
prediction interval, which is the range for the true 
effect of the intervention for 95% of similar stud-
ies in the future18. In addition, we assessed the 
small study effect with the regression asymmetry 
test proposed by Egger et al19 because small stud-
ies may overestimate the effect size. We claimed 
a small study effect with a p-value < 0.1. Pres-
ence of small study effects indicates reporting 
bias such as publication bias, poor methodologi-
cal quality of individual studies, or genuine het-
erogeneity20. We also defined the study with the 
smallest standard error as the largest study, and 
assumed that the largest study reflects the true 
effect size. The expected number of significant 
studies was obtained by multiplying the power of 
the largest study with the number of all studies 
in the meta-analysis21. We assessed the presence 
of excess significance bias which was determined 
if the observed number of studies reporting nom-
inally statistically significant result were greater 
than the expected number of studies reporting a 
significant result22,23. 
For meta-analyses of RCTs, we performed 
subgroup analyses according to the total number 
of participants (above 1,000 or below 1,000) and 
compared their results. For outcomes presented in 
both meta-analyses of RCTs and meta-analysis of 
observational studies, we compared the summary 
effects of the two study designs.
In addition, we applied credibility ceilings to 
the meta-analyses of observational studies. We 
assumed that due to inherent methods used in ob-
servational studies, any observational study could 
not give more than 100-c% (c = credibility ceil-
ing) probability of an effect being in a particular 
direction and not in the other24,25. We obtained 
the I2 index and the random-effects summary es-
timate of meta-analyses of observational studies 
under various credibility ceilings ranging from 
5% to 20%.
All statistical tests and reported p-values 
are two-sided. The software used for analysis 
was Comprehensive Meta-analysis ver.3.3.070 
(Borenstein, NH, USA), R Studio ver. 1.1.456., 
and R package “metafor” and “pwr”26-28.
Results
Selection of Eligible Meta-Analyses
We identified 1,771 articles from a PubMed, 
1,977 articles from a Embase, and 349 articles 
from a CDSR search (Figure 1). We excluded 799 
duplicate articles. From 3,298 unique articles re-
viewed by title screening, we excluded 1,460 arti-
cles not related to omega-3 fatty acids supplemen-
tation. From 1,838 articles reviewed by abstract 
screening, we excluded 1,385 articles, of which 
126 articles were conference abstracts, 399 arti-
cles did not contain respective interventions, 71 
articles did not contain meta-analyses, and 789 
articles did not contain cardiovascular outcomes. 
After the full-text screening of 453 articles, 29 ar-
ticles were finally judged to be eligible for inclu-
sion in our analysis.
From the 29 eligible articles, 83 eligible me-
ta-analyses were identified, from which data 
were extracted. From 76 meta-analyses of RCTs, 
31 (41%) were statistically significant (p < 0.05). 
Nine-teen (25%) had large heterogeneity (50% < 
I2 < 75%) and 1 (1%) had very large heterogeneity 
(I2> 75%). Seventeen (22%) had significant bias of 
small study effect. Eight (11%) had prediction in-
tervals excluding the null. Of 7 meta-analyses of 
observational cohort studies, 4 (57%) were statis-
tically significant (p < 0.05). One (14%) had large 
heterogeneity (50% < I2 < 75%) and 2 (29%) had 
very large heterogeneity (I2 > 75%). One (14%) 
had significant bias of small study effect. All 7 
(100%) lost significance under 10% credibility 
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Figure 1. Flow chart of literature search.
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ceiling. One (14%) had prediction interval exclud-
ing the null.
Determination of Cardiovascular 
Outcomes
We identified 11 cardiovascular outcomes from 
the literatures, which included cardiovascular, car-
diac, and coronary events, cardiovascular, cardiac, 
and coronary deaths, arrhythmia or sudden death, 
myocardial infarction, stroke or transient ischemic 
attack, post-operative atrial fibrillation, and recur-
rent atrial fibrillation. Although these outcomes 
were similar to each other, we followed the defini-
tion and terminology of the eligible articles as they 
were. In addition, we created a composite outcome, 
total mortality from major cardiovascular causes 
by merging component studies reporting any of 
the following: cardiovascular, cardiac, coronary, or 
sudden deaths. Eventually, we were able to analyze 
12 outcomes in the meta-analyses of RCTs and 6 
outcomes in observational cohort studies.
Total Mortality from Major Cardiovascular 
Causes in Meta-Analyses of RCTs
Meta-analyses from 5 articles were merged for 
total mortality from major cardiovascular causes. 
In total, 26 RCTs including 82,696 participants 
having more than 3,250 (> 3.9%) events were in-
cluded. The overall effect of omega-3 fatty acids 
supplementation was statistically significant (RR 
0.92, 95% Cl 0.86 to 0.98, p = 0.014) in reducing 
overall mortality of major cardiovascular causes. 
There was a low heterogeneity between compo-
nent studies (I2 = 4%), and small study effect bias 
was observed. The 95% prediction interval did 
not exclude the null (0.83 to 1.02) (Table I). There 
was no excess significance bias .
Cardiovascular Death in Meta-Analyses 
of RCTs
Meta-analyses from 3 articles were merged for car-
diovascular death. In total, 22 RCTs including 76,407 
participants with more than 3,192 (> 4.2%) events 
were included. The overall effect of omega-3 fatty ac-
ids supplementation was statistically significant (RR 
0.93, 95% CI 0.88 to 0.98, p = 0.012). There was low 
heterogeneity between component studies (I2 = 0%). 
There was small study effect bias. The 95% predic-
tion interval did exclude the null (0.87 to 0.99) (Table 
I). There was no excess significance bias.
Cardiac Death in Meta-Analyses of RCTs
Three articles derived from meta-analyses were 
merged for cardiac death. In total, 20 RCTs with 
more than 79,410 participants reported 3,618 (4.6%) 
events. The effect of omega-3 fatty acids supplemen-
tation was statistically significant (RR 0.90, 95% CI 
0.82 to 1.00, p = 0.040). Low heterogeneity between 
component studies (I2 = 20%) was found in our anal-
ysis. There was small study effect bias. The 95% pre-
diction interval did not exclude the null (0.74 to 1.10) 
(Table I). There was no excess significance bias.
Post-operative Atrial Fibrillation in 
Meta-Analyses of RCTs
Meta-analyses from 3 articles were merged for 
post-operative atrial fibrillation. In total, 21 RCTs 
with 4,201 participants were included, and a total 
of 1,247 (29.7%) events were recorded. The over-
all effect of omega-3 fatty acids supplementation 
was statistically significant (OR 0.65, 95% CI 0.51 
to 0.82, p < 0.001). There was relatively large het-
erogeneity between component studies (I2 = 53%). 
There was small study effect bias. The 95% predic-
tion interval did not exclude the null (0.29 to 1.45) 
(Table I). Excess significance bias was found.
Other Outcomes in Meta-Analyses of RCTs
Meta-analyses of the other 8 outcomes did not 
reveal significant associations, including cardio-
vascular events, cardiac events, coronary events, 
coronary deaths, arrhythmia or sudden deaths, 
myocardial infarction, stroke or transient ischemic 
attack, and recurrent atrial fibrillation (Table I). 
There was relatively large heterogeneity between 
component studies for recurrent atrial fibrillation 
(I2 = 74%), and not for the other 7 outcomes.
Total Mortality from Major 
Cardiovascular Causes 
in Meta-analyses of Cohort Studies
There was only one article reporting total mor-
tality from major cardiovascular causes. A total 
of 558,826 participants derived from 15 cohorts 
was included. The overall effect of omega-3 fatty 
acids supplementation was statistically significant 
(RR 0.76, 95% CI 0.65 to 0.90, p = 0.0013). There 
was relatively large heterogeneity between com-
ponent studies (I2 = 60%). There was no small 
study effect bias. The 95% prediction interval did 
not exclude the null (0.45 to 1.28) (Table II). A 
loss of significance under 10% credibility ceiling 
was found.
Coronary Events in Meta-Analyses 
of Cohort Studies
Again, only one article was reported for coro-
nary events. A total of 344,722 participants from 
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All statistical tests are two-sided. Bold Summary effect was statistically significant. *Presence of large heterogeneity, small study effects, or excess significance bias. Abbreviations: CI, 















I2 (%) 95% prediction interval Evaluation of biases*
Total mortality of 
major cardiovascular 
causes35-39
Overall >3,250 / 82,696 26 RR 0.92 (0.86 to 0.98) 0.014 4 0.83 to 1.02 Small study effects
Cardiovascular 
event41-45
Overall 17,033 / >72,179 39 RR 0.97 (0.92 to 1.03) 0.330 45 0.80 to 1.18 None
Cardiac event46 With coronary 
heart disease
2,852 / 25,134 10 OR 0.92 (0.79 to 1.06) 0.250 49 0.63 to 1.33 None
Coronary event45 Overall 6,093 / 77,917 10 RR 0.95 (0.89 to 1.03) 0.210 0 0.88 to 1.04 None
Cardiovascular 
death35,38,39
Overall >3,192 / 76,407 22 RR 0.93 (0.88 to 0.98) 0.012 0 0.87 to 0.99 Small study effects
Cardiac death36,37,47 Overall 3,618 / 79,410 20 RR 0.90 (0.82 to 1.00) 0.040 20 0.74 to 1.10 Small study effects
Coronary death45 Overall 2,695 / 77,917 10 RR 0.93 (0.84 to 1.03) 0.150 0 0.82 to 1.05 None
Arrhythmia or 
sudden death46,48,49
Overall 1,415 / 43,987 12 OR 0.85 (0.71 to 1.02) 0.086 32 0.57 to 1.28 None
Myocardial 
infarction38,45,47
Overall 2,846 / 86,411 20 RR 0.90 (0.80 to 1.00) 0.056 13 0.72 to 1.12 None
Stroke or transient 
ischemic attack41,47














894 / 1,990 8 OR 0.81 (0.52 to 1.25) 0.340 74 0.21 to 3.14 Large heterogeneity
Table I. Meta-analyses of randomized controlled trials of omega-3 fatty acids on major cardiovascular outcomes.
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14 cohorts was included. The overall effect of 
omega-3 fatty acids supplementation was statis-
tically significant (RR 0.89, 95% CI 0.84 to 0.96, 
p = 0.001). A low heterogeneity between compo-
nent studies (I2 = 3%) was found. There was no 
small study effect bias. The 95% prediction in-
terval excluded the null (0.82 to 0.98) (Table II). 
There was a loss of significance under 10% cred-
ibility ceiling. 
Coronary Deaths in Meta-Analyses 
of Cohort Studies
There was only one article reporting coronary 
deaths. A total of 357,621 participants from 10 co-
horts was included. The overall effect of omega-3 
fatty acids supplementation was statistically sig-
nificant (RR 0.85, 95% CI 0.73 to 1.00, p = 0.047). 
There was no large heterogeneity between com-
ponent studies (I2 = 49%), nor small study effect 
bias. The 95% prediction interval did not exclude 
the null (0.57 to 1.29) (Table II). There was a loss 
of significance under 10% credibility ceiling.
Arrhythmia or Sudden Deaths in 
Meta-Analyses of Cohort Studies
There was only one article reporting on ar-
rhythmia or sudden deaths. In total, 201,205 par-
ticipants of 5 cohorts were included. The overall 
effect of omega-3 fatty acids supplementation was 
statistically significant (RR 0.53, 95% CI 0.41 to 
0.67, p < 0.001). There was no heterogeneity be-
tween component studies (I2 = 0%). There was no 
small study effect bias. The 95% prediction inter-
val excluded the null (0.36 to 0.78) (Table II). A 
loss of significance under 10% credibility ceiling 
was found.
Other Outcomes in Meta-Analyses 
of Cohort Studies
Both other outcomes, cardiovascular events 
and myocardial infarction, were not statistically 
significant (Table II). There was very large het-
erogeneity between component studies of cardio-
vascular events (I2 = 77%), and relatively large 
heterogeneity between component studies of 
myocardial infarction (I2 = 72%).
Comparison of Meta-Analyses Between 
RCTs and Cohort Studies
Twelve outcomes have been reviewed from 
the meta-analyses of RCTs, and 6 outcomes have 
been reviewed from the meta-analyses of cohort 
studies. From the 6 overlapping outcomes, only 
1 outcome of a meta-analysis of RCTs and 4 out-
comes of meta-analyses of cohort studies showed 
statistical significance (p < 0.05 for random-ef-
fect model) (Table III). For the outcome of total 
mortality of major cardiovascular causes, the 
meta-analysis of RCTs and cohort studies both 
showed statistical significance. For the outcomes 
of coronary events, coronary deaths, and arrhyth-
mia or sudden deaths, only meta-analyses of co-
hort studies showed statistical significance while 
meta-analyses of RCTs did not. For the outcomes 
of cardiovascular event and myocardial infarc-
tion, both meta-analyses of RCTs and cohort stud-
ies did not show statistical significance (Figure 2).
Comparison of Meta-Analyses Between 
RCTs with More Than 1,000 Participants 
and Less than 1,000 Participants
While the effect sizes reported from the larg-
est cohort studies were similar compared to the 
meta-analyses of cohort studies, the discrepancy 
was present between the effect size reported from 
the largest RCTs and the meta-analyses of RCTs, 
which underlines the need for subgroup analysis 
according to the number of total participants (> 
1,000 vs. < 1,000) (Table III and Figure 2). 
Out of all 12 major cardiovascular outcomes, 
total mortality from major cardiovascular causes, 
cardiovascular death, cardiac death, and postop-
erative atrial fibrillation showed statistical signif-
icance in meta-analyses of RCTs with less than 
1,000 participants, whereas only 2 outcomes were 
still supported by statistically significance even in 
meta-analyses of RCTs of total participants larger 
than 1,000. These 2 outcomes were total mortali-
ty from major cardiovascular causes (RR = 0.94, 
95% CI 0.88 to 0.99) and cardiovascular deaths 
(RR = 0.94, 95% CI 0.89 to 1.00) (Table III).
Notably, there was a tendency for the me-
ta-analyses of RCTs with less than 1,000 partic-
ipants to report a dramatically larger effect size 
(RR = 0.58 for total mortality of major cardiovas-
cular causes, RR = 0.61 for cardiovascular death, 
RR = 0.60 for cardiac death) compared to those 
with more than 1,000 participants (RR = 0.94 for 
total mortality from major cardiovascular causes, 
RR = 0.94 for cardiovascular death, RR = 0.93 for 
cardiac death) (Table III). These 2 outcomes had 
small study effects as well. 
Nonetheless, when subgroup analysis was con-
ducted with RCTs of more than 1,000 patients, 
statistical significance for total mortality from 
major cardiovascular causes was maintained (p 
= 0.033) with low heterogeneity (I2 = 0%), and 
there was no small study effect. As for cardio-
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Table II. Meta-analyses of cohort studies of omega-3 fatty acids on major cardiovascular outcomes. .
    Number of  Random Random  95%
Cardiovascular  Events/total study Effect effects summary  effects  prediction  Evaluation of
outcome Population population estimates metrics estimate (95% CI) p value I2 (%) interval  biases*
        
Total mortality  Non-hospitalized NR/558,826 15 RR 0.76 (0.65 to 0.90) < 0.001 60 0.45 to 1.28 Large
from major  adults of at least        heterogeneity
cardiovascular  18 years old
causes54       
Cardiovascular Overall 1842/68,954 6 RR 0.97 (0.78 to 1.21) 0.800 77 0.49 to 1.94 Large heterogeneity
event41
Coronary event55 Overall NR/344,722 14 RR 0.89 (0.84 to 0.96) 0.001 3 0.82 to 0.98 Loss of significance
         under 10% credibility
         ceiling
Coronary death54 Non-hospitalized  NR/357,621 10 RR 0.85 (0.73 to 1.00) 0.047 49 0.57 to 1.29 Loss of significance
 adults of at least         under 10% 
 18 years old        credibility ceiling
Arrhythmia or Non-hospitalized  NR / 201,205 5 RR 0.53 (0.41 to 0.67) < 0.001 0 0.36 to 0.78 Loss of
sudden death54  adults of at least         significance under
 18 years old        10% credibility 
         ceiling
Myocardial  Non-hospitalized NR/274,083 7 RR 0.91 (0.74 to 1.11) 0.340 72 0.48 to 1.70 Large heterogeneity
infarction54 adults of at least 
 18 years old  
All statistical tests are two-sided. Bold Summary effect was statistically significant. *Large heterogeneity, small study effects,  excess significance bias, or loss of heterogeneity 
under 10% credibility ceiling. Abbreviations: CI, confidence interval; NR, not reported; OR, odds ratio; RR, risk ratio.
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Figure 2. Forest plot of meta-analyses of randomized controlled trials and cohort studies for all the categories of major cardiovascular outcomes.
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Table III. Comparison and Subgroup analyses of randomized controlled trials and cohort studies.




of RCTs The largest RCT




of RCTs with 
participants < 1,000
Metric Meta-analysis of cohort studies
The largest cohort 
study
Total mortality from 
major cardiovascular
causes
RR 0.92 (0.86 to 0.98)* 0.93 (0.85 to 1.02) 0.94 (0.88 to 0.99)* 0.58 (0.42 to 0.81)* RR 0.76 (0.65 to 0.90)* 0.86 (0.77 to 0.96)*
Cardiovascular event RR 0.97 (0.92 to 1.03) 0.97 (0.93 to 1.02) 0.99 (0.94 to 1.04) 0.86 (0.71 to 1.03) RR 0.97 (0.78 to 1.21) 1.12 (0.95 to 1.32)
Cardiac event OR 0.92 (0.79 to 1.06) 0.89 (0.79 to 1.01) 0.96 (0.82 to 1.13) 0.72 (0.50 to 1.03) NA NA NA
Coronary event RR 0.95 (0.89 to 1.03) 0.93 (0.82 to 1.06) 0.95 (0.89 to 1.03) NA RR 0.89 (0.84 to 0.96)* 0.81 (0.72 to 0.91)*
Cardiovascular death RR 0.93 (0.88 to 0.98)* 0.93 (0.85 to 1.02) 0.94 (0.89 to 1.00)* 0.61 (0.43 to 0.85)* NA NA NA
Cardiac death RR 0.90 (0.82 to 1.00) 0.92 (0.84 to 1.02) 0.93 (0.84 to 1.02) 0.60 (0.41 to 0.87)* NA NA NA
Coronary death RR 0.93 (0.84 to 1.03) 0.91 (0.77 to 1.08) 0.93 (0.84 to 1.03) NA RR 0.85 (0.73 to 1.00)* 0.86 (0.77 to 0.96)*
Arrhythmia or sudden 
death OR 0.85 (0.71 to 1.02) 0.94 (0.80 to 1.11) 0.88 (0.77 to 1.00) 0.76 (0.48 to 1.18) RR 0.53 (0.41 to 0.67)* 0.50 (0.35 to 0.71)*
Myocardial infarction RR 0.90 (0.80 to 1.00)* 0.75 (0.62 to 0.90)* 0.90 (0.82 to 1.00) 0.74 (0.42 to 1.31) RR 0.91 (0.74 to 1.11) 1.16 (0.99 to 1.36)
Stroke or transient 
ischemic attack RR 1.20 (0.94 to 1.53) 1.19 (0.88 to 1.61) 1.23 (0.94 to 1.59) 1.00 (0.48 to 2.08) NA NA NA
Postoperative atrial 
fibrillation OR 0.65 (0.51 to 0.82)* 0.96 (0.77 to 1.19) NA 0.62 (0.48 to 0.80)* NA NA NA
Recurrent atrial 
fibrillation OR 0.81 (0.52 to 1.25) 1.29 (0.95 to 1.76) NA 0.81 (0.52 to 1.25) NA NA NA
All statistical tests are two-sided. Underline means overlapping outcomes. *Summary effect was statistically significant (p < 0.05). Abbreviations: NA, not available; OR, odds ratio; RCT, 
randomized controlled trial; RR, risk ratio.
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vascular deaths, statistical significance was also 
maintained (p = 0.043) with low heterogeneity (I2 
= 0%), and there was no small study effect.
Discussion
Even though a clear clinical benefit has not 
been established, it has been assumed that ome-
ga-3 fatty acids supplementation might have some 
beneficial effect on cardiovascular outcomes29. 
However, previous large clinical trials demon-
strated no evidence of the effect of omega-3 fatty 
acids supplementation on various cardiovascular 
outcomes. The OMEGA trial, a randomized, pla-
cebo-controlled, double-blind, multicenter trial 
included 3,851 participants with one year of fol-
low-up and concluded that omega-3 fatty acids 
supplementation did not reduce sudden cardiac 
deaths and cardiovascular events6. The ORIGIN 
trial concluded that omega-3 fatty acids supple-
mentation did not reduce cardiovascular events 
in patients with dysglycemia7. The Risk and Pre-
vention Study trial concluded that omega-3 fatty 
acids supplementation did not reduce cardiovas-
cular mortality8. Even the VITAL trial, the most 
recently conducted clinical trial of omega-3 fatty 
acids, showed that omega-3 fatty acids supple-
mentation did not reduce the incidence of major 
cardiovascular events9.
There have been 3 umbrella reviews compar-
ing the effects of various nutrients including ome-
ga-3 and cardiovascular outcome to date30-32, but 
to the best of our knowledge, an umbrella review 
focusing only omega-3 effects on cardiovascular 
outcomes has not been conducted. In particular, 
in this current review study, we aimed to iden-
tify true associations between omega-3 fatty ac-
ids and cardiovascular outcome more strictly by 
excluding biases and performing subgroup anal-
yses. Furthermore, we comprehensively analyzed 
previous literature by including RCTs as well as 
observational cohort studies.
In our study, total mortality from major car-
diovascular causes showed statistical significance 
from meta-analyses of cohort studies despite 
large heterogeneity. In addition, the meta-analy-
ses of RCTs also showed that total mortality from 
major cardiovascular causes was reduced by ome-
ga-3 fatty acids supplementation with statistical 
significance. Furthermore, when we performed 
subgroup-analyses to verify the reliability of ev-
idence more strictly, statistical significance was 
maintained even in the case of RCTs with more 
than 1,000 participants. From the meta-analyses of 
RCTs with more than 1,000 participants, the bias 
of small study effects was not detected, showing 
that the significant effects were persistent among 
the large-sized RCTs without any significant bias 
that had to be considered during the review.
Interestingly, in our umbrella review, most car-
diovascular outcomes other than mortality did 
not show significant associations with omega-3 
fatty acids supplementation. Rather, only mor-
tality from cardiovascular causes had an inverse 
relationship with omega-3 fatty acids supplemen-
tation. The result is somewhat intriguing because 
mortality was reduced by omega-3 fatty acids 
supplementation, while less severe cardiac events 
were not affected. Although we are not sure of 
the exact reason for such a paradoxical result, we 
can consider the possibility that it may be due to 
the differences in clarity of clinical presentation 
and probability of diagnosis of each outcome. 
For example, severe diseases such as myocardial 
infarction are usually well-diagnosed with clear 
clinical manifestations, whereas less severe dis-
eases such as ischemic heart disease and transient 
ischemic attack often have sub-clinical presenta-
tion and may not have been properly diagnosed 
due to silent symptoms. On the other hand, death 
is an uncontroversial clinical outcome and the di-
agnosis is definitive. In this case, mortality may 
be a more reliable outcome and may reflect more 
accurately the clinical effect of a medical inter-
vention. We believe that our study may have had 
paradoxical results for this same reason, and that 
the significant reduction in mortality by omega-3 
supplementation is reliable even in the absence of 
clinical significance for other relevant outcomes.
Strengths and Limitations
This umbrella review is distinct from the prior 
umbrella review, since we examined the effect of 
only omega-3 fatty acids on various cardiovas-
cular outcomes of specific causes. A recent com-
prehensive meta-analysis11 studied the effect of 
omega-3 fatty acids on cardiovascular outcomes, 
which included individual studies assessing di-
etary interventions such as advising to increase 
oily fish consumption, while we focused on the 
effects of omega-3 fatty acids supplement only. 
The meta-analysis11 concluded that alpha-linole-
nic acid, a type of omega-3 fatty acids, reduces 
coronary heart disease mortality, prevalence of 
arrhythmia, and cardiovascular disease events. 
However, this might not necessarily mean that 
these beneficial effects are the results of omega-3 
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fatty acids intake, because fish intake is nutritional-
ly different from omega-3 fatty acids intake alone. 
There is evidence from a RCT12 that fish intake of 
500g per week has beneficial effects on cardiovas-
cular outcomes, while omega-3 fatty acids supple-
mentation dose not. Indeed, during the literature 
research, we identified several articles33,34 which 
concluded that omega-3 fatty acids intake was ben-
eficial in preventing cardiovascular disease but in-
cluded component studies of dietary interventions 
in their meta-analyses, which may not act as suf-
ficient evidence for the effect of the omega-3 fatty 
acids alone on cardiovascular outcome. 
This umbrella review has advantages over pre-
vious meta-analyses because it includes quantita-
tive analyses of all non-overlapping component 
studies derived from meta-analyses showing 
different conclusions. Several previous articles 
concluded that omega-3 fatty acids supplemen-
tation has a beneficial effect on cardiovascular 
outcomes, based on the statistically significant 
results of their meta-analyses. Among the eligible 
meta-analyses in our review, evidence of RCTs 
studying the association with omega-3 fatty acids 
supplementation and total mortality from major 
cardiovascular events were studied by a total of 
five articles, with two of them concluding signifi-
cant associations35,36 and three of them concluding 
non-significant associations37-39. Our meta-analy-
sis included all non-overlapping component stud-
ies from the meta-analyses of these 5 articles and 
showed that the association was statistically sig-
nificant, even when the analysis was restricted to 
RCTs with more than 1,000 patients. In addition, 
the association of omega-3 fatty acids supplemen-
tation and cardiovascular events was studied by a 
total of 6 articles. One of these studies concluded 
a statistically significant association40, while 5 of 
them found non-significant associations41-45. In 
our meta-analysis that included all non-overlap-
ping component studies from the meta-analyses 
of these 6 articles, we found that the association 
was not statistically significant, implying that 
there was no significant positive effect of omega-3 
fatty acids supplementation on the overall number 
of cardiovascular events. 
There are several limitations which need to 
be taken into account. First, we systematically 
searched and identified results of meta-analyses, 
which means that recent clinical trials might have 
been overlooked. However, for the outcomes of 
total mortality of cardiac causes, cardiovascular 
events, coronary events, cardiovascular deaths, 
coronary deaths, and myocardial infarctions, we 
identified and included meta-analyses published 
in 2018, so it is likely that this review includes 
recent clinical trials for these outcomes. Addi-
tionally, we also have conducted meta-analyses 
including the latest trial9 reported on January 3rd, 
2019. This RCT reported five major cardiovascu-
lar outcomes, total mortality from cardiovascu-
lar causes, cardiovascular events, cardiovascular 
deaths, myocardial infarctions, stroke or transient 
ischemic attack. The results of meta-analyses 
were not different from the previous meta-anal-
yses we had. Second, we did not evaluate the 
quality of individual component studies, which 
is the responsibility of the authors of the original 
meta-analyses and was beyond the scope of our 
review. Third, because we did not list and con-
sider the amount of fish consumption, we could 
not deny the possibility that the random effect of 
fish consumption could be greater and obscured 
the effect of omega-3 fatty acids, which could be 
a strong reason why various outcomes were not 
statistically significant.
Conclusions
Our umbrella review indicates that omega-3 
fatty acids supplementation reduces overall mor-
tality from cardiovascular causes. Even though a 
few large RCTs showed no evidence of clinical ef-
fect of omega-3 on cardiovascular outcomes, our 
comprehensive review study still provides a clue 
of clinical utility of omega-3 fatty acids supple-
mentation. Considering that there have been con-
flicting results in many existing studies, in future 
clinical trials, it is necessary to identify the true 
clinical evidence concerning omega-3 fatty acids 
supplementation through efforts to reduce various 
research biases.
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